2,6-Dimethyl-4-(2-nitro-vinyl)-phenol | 90922-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: 2,6-Dimethyl-4-(2-nitro-vinyl)-phenol
• 英文别名: 2,6-Dimethyl-4-(2-nitrovinyl)phenol；2,6-dimethyl-4-(2-nitroethenyl)phenol
• CAS: 90922-56-8
• 化学式: C₁₀H₁₁NO₃
• 分子量: 193.202
• InChiKey: ULOPZCZOKDOQOX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-Dimethyl-4-(2-nitro-vinyl)-phenol 在 aluminum (III) chloride 、 lithium aluminium tetrahydride 、 盐酸 作用下， 以 四氢呋喃 、 甲苯 、 正丁醇 为溶剂， 反应 16.0h， 生成 3,5-dimethyltyramine hydrochloride
  参考文献：
  名称：

  Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma

  摘要：

  Respiratory failure due to pulmonary metastasis is the major cause of death for patients with osteosarcoma. However, the molecular basis for metastasis of osteosarcoma is poorly understood. Recently, ezrin, a member of the ERM family of proteins, has been associated with osteosarcoma metastasis to the lungs. The small molecule NSC 668394 was identified to bind to ezrin, inhibit in vitro and in vivo cell migration, invasion, and metastatic colony survival. Reported herein are the design and synthesis of analogues of NSC 668394, and subsequent functional ezrin inhibition studies. The binding affinity was characterized by surface plasmon resonance technique. Cell migration and invasion activity was determined by electrical cell impedance methodology. Optimization of a series of heterocyclic-dione analogues led to the discovery of compounds 21k and 21m as potential novel antimetastatic agents. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.11.003
• 作为产物：
  描述：

  硝基甲烷 、 3,5-二甲基-4-羟基苯甲醛 在 ammonium acetate 、 溶剂黄146 作用下， 反应 2.0h， 生成 2,6-Dimethyl-4-(2-nitro-vinyl)-phenol
  参考文献：
  名称：

  Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma

  摘要：

  Respiratory failure due to pulmonary metastasis is the major cause of death for patients with osteosarcoma. However, the molecular basis for metastasis of osteosarcoma is poorly understood. Recently, ezrin, a member of the ERM family of proteins, has been associated with osteosarcoma metastasis to the lungs. The small molecule NSC 668394 was identified to bind to ezrin, inhibit in vitro and in vivo cell migration, invasion, and metastatic colony survival. Reported herein are the design and synthesis of analogues of NSC 668394, and subsequent functional ezrin inhibition studies. The binding affinity was characterized by surface plasmon resonance technique. Cell migration and invasion activity was determined by electrical cell impedance methodology. Optimization of a series of heterocyclic-dione analogues led to the discovery of compounds 21k and 21m as potential novel antimetastatic agents. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2013.11.003

文献信息

• Antitumor Agent
  申请人：Arai Hitoshi

  公开号：US20090012060A1

  公开（公告）日：2009-01-08

  The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): [wherein —X—Y-Z- represents —O—CR 3 ═N— (wherein R 3 represents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, R 1 represents —NR 10 R 11 (wherein R 10 and R 11 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like) and the like, R 2 represents —NR 13 R 14 (wherein R 13 and R 14 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种抗肿瘤剂及类似物，其包括一种以嘧啶衍生物为活性成分，其表示为式（I）：[其中- X-Y-Z-表示-O-CR3═N-（其中R3表示氢原子，取代或未取代的芳香族杂环基等），R1表示-NR10R11（其中R10和R11可以相同或不同，且每个表示氢原子，取代或未取代的较低烷基等），R2表示-NR13R14（其中R13和R14可以相同或不同，且每个表示氢原子，取代或未取代的较低烷基等）]或其药学上可接受的盐。
• Pyrimidine derivative compound
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US07956060B2

  公开（公告）日：2011-06-07

  The present invention provides an antitumor agent and the like, which comprises as an active ingredient, a pyrimidine derivative represented by Formula (I): [wherein —X—Y—Z— represents —O—CR3═N— (wherein R3 represents a hydrogen atom, a substituted or unsubstituted aromatic heterocyclic group and the like) and the like, R1 represents —NR10R11 (wherein R10 and R11 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like) and the like, R2 represents —NR13R14 (wherein R13 and R14 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl and the like)] or a pharmaceutically acceptable salt thereof.

  本发明提供了一种抗肿瘤剂等，其包括作为活性成分的嘧啶衍生物，该衍生物由式（I）表示：[其中—X—Y—Z—表示—O—CR3═N—（其中R3表示氢原子，取代或未取代的芳香族杂环基等），R1表示—NR10R11（其中R10和R11可以相同或不同，每个表示氢原子，取代或未取代的较低烷基等），R2表示—NR13R14（其中R13和R14可以相同或不同，每个表示氢原子，取代或未取代的较低烷基等）]或其药学上可接受的盐。
• Design, synthesis and biological evaluation of ezrin inhibitors targeting metastatic osteosarcoma
  作者：Mikell Paige、George Kosturko、Güllay Bulut、Matthew Miessau、Said Rahim、Jeffrey A. Toretsky、Milton L. Brown、Aykut Üren

  DOI：10.1016/j.bmc.2013.11.003

  日期：2014.1

  Respiratory failure due to pulmonary metastasis is the major cause of death for patients with osteosarcoma. However, the molecular basis for metastasis of osteosarcoma is poorly understood. Recently, ezrin, a member of the ERM family of proteins, has been associated with osteosarcoma metastasis to the lungs. The small molecule NSC 668394 was identified to bind to ezrin, inhibit in vitro and in vivo cell migration, invasion, and metastatic colony survival. Reported herein are the design and synthesis of analogues of NSC 668394, and subsequent functional ezrin inhibition studies. The binding affinity was characterized by surface plasmon resonance technique. Cell migration and invasion activity was determined by electrical cell impedance methodology. Optimization of a series of heterocyclic-dione analogues led to the discovery of compounds 21k and 21m as potential novel antimetastatic agents. (C) 2013 Elsevier Ltd. All rights reserved.